Skip to content

Development of Psycho-social Support Program for Patients and Caregivers of Myotonic Dystrophy Type 1

Development of Psycho-social Support Program for Patients and Caregivers of Myotonic Dystrophy Type 1 - DM Psycho-social Support Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049167
Enrollment
20
Registered
2022-10-11
Start date
2022-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic dystrophy type 1

Interventions

Patients and caregivers receive from interventional staffs the support program sessions (approximately 10 sessions) which each lasts for an hour, with a frequency of once a week to once a month.

Sponsors

National Center of Neurology and Psychiatry
Lead Sponsor
National Hospital Organization, Aomori Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients and caregivers who are able to fully understand the contents of the informed consent document and from whom written consent is obtained before participation. 2) Both patient and caregiver agree to participate in the study. 3) Patients and caregivers aged 18 or older at the time of informed consent. 4) Patients who are diagnosed with DM1 by genetic testing (DMPK gene). 5) Patients who are able to move independently by walking or using an assistive device/wheelchair. 6) A caregiver is defined as "a family member, relative, partner, or friend who lives with the patient, who is not in a caregiving profession, and who reduces the patient's burden due to illness regardless of the level of care provided".

Exclusion criteria

Exclusion criteria: 1) If either the patient or caregiver is unwilling to participate in the study. 2) If patient has intake of antipsychotics and/or mood stabilizers. 3) If there was a change in dosage of antidepressants, anti-anxiety drugs, sleeping pills, Modafinil, and Ritalin in the past 12 months. However, intake of as-needed anxiolytics and sleeping pills are allowed. 4) If the caregiver is in caregiving profession. 5) Other cases in which the principal investigator or research co-investigator determines that the participant is not suitable for study participation.

Design outcomes

Primary

MeasureTime frame
Activity and Participation: Frenchay Activities Index

Secondary

MeasureTime frame
Fatigue: Fatigue Severity Scale Daytime Sleepiness: Epworth Sleepiness Scale QOL: SF-12v2 Apathy: Apathy Evaluation Scale Caregiver version Cognitive ability: Mini Mental State Examination Caregiving burden: Zarit Caregiver Burden Short version

Countries

Japan

Contacts

Public ContactMakiko Endo

National Center of Neurology and Psychiatry Hospital, Clinical Research Unit

endo@ncnp.go.jp042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026